Hologic Announces Financial Results for Second Quarter of Fiscal 2023

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended April 1, 2023.

“Our fiscal second quarter of 2023 once again made clear the strength and durability in each one of our businesses”.

“Hologic posted robust financial results in our second fiscal quarter, with both revenue and earnings exceeding our prior guidance,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “Each of our core franchises grew double digits in the period, with consolidated organic growth of more than 20%, excluding the impact of COVID. Our Breast Health and Surgical businesses delivered exceptional performance, both growing over 23% – or over 25% in constant currency, and our Diagnostics business again delivered strong results. We are also pleased to increase our full-year guidance once again.”

Recent Highlights

  • Revenue of $1,026.5 million decreased (28.5%) for the quarter, or (27.5%) in constant currency, primarily driven by significantly lower sales of COVID-19 assays, which was expected, compared to the prior year period. Revenue, however, was notably higher than the Company’s guidance of $930 to $980 million provided last quarter.
    • Excluding COVID-19 revenues, total organic revenue grew 20.2%, or 21.9% on a constant currency basis.
  • Diagnostics revenue decreased (52.9%), or (52.2%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
    • Excluding COVID-19 revenues, Diagnostics revenue grew 14.9% on an organic, constant currency basis.
    • Molecular Diagnostics revenue declined (60.3%), or (59.8%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
    • Excluding COVID-19 revenues, Molecular Diagnostics revenue grew 23.9% on an organic, constant currency basis.
  • Breast Health revenue increased 24.2%, or 25.7% in constant currency, primarily due to improving semiconductor chip supply enabling additional gantry deliveries within the quarter, resulting in higher capital equipment revenue compared to the prior year period.
  • Surgical revenue grew 23.4%, or 25.2% in constant currency, with strong results across an increasingly diverse business.
  • Cash flow from operations remained very strong in the second quarter at $206.3 million. In addition, the Company repurchased 0.6 million shares of its stock for $50 million in the quarter.
  • The Company was named on the Forbes list of America’s Best Midsize Employers 2023 and was ranked 14th among 500 midsize companies included on the list.
  • The Company published its latest annual sustainability report, “Making a World of Difference.”

Key financial results for the fiscal second quarter are shown in the table below.

 Q2’23 Q2’22 Change
 Q2’23 Q2’22 Change
Revenues$1,026.5 $1,435.7 (28.5%) $1,026.5 $1,435.7 (28.5%)
Gross Margin57.1% 65.9% (880 bps) 62.1% 71.0% (890 bps)
Operating Expenses$313.7 $352.5 (11.0%) $317.0 $338.2 (6.3%)
Operating Margin26.5% 41.4% (1,490 bps) 31.3% 47.4% (1,610 bps)
Net Margin21.3% 31.7% (1,040 bps) 25.9% 36.5% (1,060 bps)
Diluted EPS$0.87 $1.80 (51.7%) $1.06 $2.07 (48.8%)

Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Fiscal 2023 is a 53-week fiscal period and the additional week was included in our fiscal first quarter results. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Our fiscal second quarter organic revenue results exclude the divested Blood Screening business. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition.

Revenue Detail

    Increase (Decrease)
$ in millions Q2’23 Q2’22 Global
Cytology and Perinatal$111.9 $115.4 (3.0%) (0.7%) (4.3%) (0.7%) 5.4%
Molecular Diagnostics$342.2 $862.5 (60.3%) (59.8%) (53.3%) (73.5%) (71.9%)
Blood Screening$10.6 $9.2 15.2% 15.2% 15.2% N/A N/A
Total Diagnostics$464.7 $987.1 (52.9%) (52.2%) (46.9%) (64.3%) (62.1%)
Organic Diagnostics ex. COVID-19$355.0 $314.2 13.0% 14.9% 14.2% 10.1% 16.6%
Breast Health             
Breast Imaging$311.5 $245.0 27.1% 28.8% 24.6% 35.4% 42.5%
Interventional Breast Solutions$73.9 $65.4 13.0% 13.9% 14.6% 5.4% 11.0%
Total Breast Health$385.4 $310.4 24.2% 25.7% 22.4% 29.7% 36.6%
GYN Surgical$144.8 $117.3 23.4% 25.2% 20.9% 33.6% 42.5%
Skeletal Health$31.6 $20.9 51.2% 53.4% 39.4% 74.5% 80.4%
Total$1,026.5 $1,435.7 (28.5%) (27.5%) (22.5%) (41.9%) (38.5%)
Organic Revenue (definition above)$1,015.9 $1,426.5 (28.8%) (27.7%) (22.9%) (41.9%) (38.5%)
Organic Revenue excluding COVID-19$916.8 $762.8 20.2% 21.9% 19.4% 22.6% 29.5%

Other Financial Highlights

  • U.S. revenue of $768.7 million decreased (22.5%). International revenue of $257.8 million decreased (41.9%), or (38.5%) in constant currency.
  • GAAP gross margin of 57.1% decreased (880) basis points. Non-GAAP gross margin of 62.1% decreased (890) basis points. The decrease in gross margin was primarily due to the decline in COVID-19 assay sales compared to the prior year period.
  • GAAP operating margin of 26.5% decreased (1,490) basis points. Non-GAAP operating margin of 31.3% decreased (1,610) basis points. The decrease in operating margin was primarily due to the decline in COVID-19 assay sales compared to the prior year period.
  • GAAP net income of $218.5 million decreased (52.1%). Non-GAAP net income of $265.7 million decreased (49.3%). GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $355.8 million. Adjusted EBITDA was $345.4 million, a decrease of (50.9%).
  • COVID-19 revenues, which consist of COVID-19 assay revenue of $71.2 million, and other COVID-19 related revenue and revenue from discontinued products of $27.9 million, decreased (85.1%), or (84.8%) in constant currency.
  • Total principal debt outstanding at the end of the second quarter was $2.84 billion. The Company ended the quarter with cash and equivalents of $2.58 billion, and a net leverage ratio (net debt over EBITDA) of 0.2 times.
  • On a trailing 12-month basis, GAAP Return on Invested Capital (ROIC) was 14.0%. Adjusted ROIC was 14.4%, a decrease of (1,300) basis points compared to the prior year period.

Financial Guidance for the Third Quarter and Full-Year Fiscal 2023

“Our fiscal second quarter of 2023 once again made clear the strength and durability in each one of our businesses,” said Karleen Oberton, Hologic’s chief financial officer. “We are raising our full-year guidance for both revenue and EPS, highlighting our confidence in the remainder of our fiscal year despite an uncertain macro environment.”

Hologic’s financial guidance for the third quarter and full year 2023 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.0%, and diluted shares outstanding of 250 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2023 as in fiscal 2022. Organic revenue guidance is in constant currency and excludes the divested Blood Screening business. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. In fiscal 2023, Bolder is part of organic revenue starting in the fiscal second quarter.

 Current Guidance Previous Guidance
 Guidance $ Reported %
 Constant Currency
% Increase
 Organic %
 Guidance $
Fiscal 2023         
Revenue$3,925 – $4,025 (19.3%) to (17.2%) (18.5%) to (16.4%) (18.7%) to (16.6%) $3,850 – $4,000
GAAP EPS$2.91 – $3.11 (43.3%) to (39.4%)     $2.69 – $2.99
Non-GAAP EPS$3.75 – $3.95 (37.7%) to (34.4%)     $3.55 – $3.85
Q3 2023         
Revenue$930 – $980 (7.2%) to (2.3%) (6.9%) to (1.9%) (6.8%) to (1.8%)  
GAAP EPS$0.64 – $0.74 (28.9%) to (17.8%)      
Non-GAAP EPS$0.83 – $0.93 (12.6%) to (2.1%)      

This guidance assumes low double-digit constant currency organic revenue growth ex. COVID-19 for the total Company for the full-year fiscal 2023.

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; adjusted EBITDA; and adjusted ROIC. Organic revenue for the fiscal second quarter of 2023 excludes the divested Blood Screening business. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 revenues is organic revenue less COVID assay revenue, COVID related sales of instruments, collection kits and ancillaries, COVID related revenue from Diagenode and Mobidiag, as well as COVID related license revenue, and revenues from discontinued products. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill and intangible assets; (ii) adjustments to record contingent consideration at fair value; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value; (iv) restructuring charges, facility closure and consolidation charges (including accelerated depreciation), and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services); (v) expenses related to the divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters; (vi) transaction related expenses for acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of foreign currency contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impacts related to internal restructurings and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company’s core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines its adjusted ROIC as its non-GAAP operating income tax effected by its non-GAAP effective tax rate divided by the sum of its average net debt and stockholders’ equity, which is adjusted to exclude the effects of goodwill and intangible impairment charges.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Hologic’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic’s business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the second quarter of fiscal 2023. Interested participants may listen to the call by dialing 888-600-4862 (in the U.S. and Canada) or +1 773-305-6865 (for international callers) and referencing access code 2312014. Participants may also click to join. Participants should dial in 5-10 minutes before the call begins. The Company will also provide a live webcast of the call at investors.hologic.com. A replay of the call will be available at investors.hologic.com approximately two hours after the call ends through Monday, May 29, 2023.

Souce: https://www.businesswire.com/

Newsletter Updates

Enter your email address below and subscribe to our newsletter